A human urinary protease inhibitor (ulinastatin) inhibits neutrophil extracellular release of elastase during cardiopulmonary bypass

Atsuko Hiyama, Junzo Takeda, Yoshifumi Kotake, Hiroshi Morisaki, Kazuaki Fukushima

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Objectives: To determine the benefits of a human urinary protease inhibitor (ulinastatin) on postoperative pulmonary dysfunction associated with neutrophil activation during cardiopulmonary bypass. Design: A prospective, randomized, clinical study. Setting: The study was performed at Keio University Hospital, Tokyo. Participants: Eighteen adult patients scheduled for primary cardiac surgery. Interventions: The patients were randomly assigned either to the control group (n = 8) or to the group (n = 10) receiving ulinastatin (600,000 U in total). Measurements and Main Results: Human neutrophil ability to release elastase in response to N- formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP) in vitro was measured before and after cardiopulmonary bypass, together with plasma levels of neutrophil elastase complex, interleukin-8, and C3a. Intrapulmonary shunt fraction was then calculated. Neutrophil elastase release in response to fMLP significantly increased in the control group, but remained unchanged in the ulinastatin group. In addition, ulinastatin minimized the increase of plasma neutrophil elastase, independently of the production of interleukin-8 or C3a. Simultaneously, ulinastatin ameliorated the increase of intrapulmonary shunt, which was correlated with extracellular elastase release. Conclusions: Ulinastatin attenuated the elevation of fMLP-induced elastase release, which was associated with the deterioration of gas exchange during cardiopulmonary bypass. The administration of this agent has a potential to lessen the risk of postperfusion lung injury.

Original languageEnglish
Pages (from-to)580-584
Number of pages5
JournalJournal of Cardiothoracic and Vascular Anesthesia
Volume11
Issue number5
DOIs
Publication statusPublished - 1997 Aug

Fingerprint

Pancreatic Elastase
Protease Inhibitors
Cardiopulmonary Bypass
leucyl-phenylalanine
Neutrophils
Leukocyte Elastase
Phenylalanine
Interleukin-8
Neutrophil Activation
Control Groups
Tokyo
Lung Injury
Thoracic Surgery
urinastatin
Gases
Lung

Keywords

  • Cardiopulmonary bypass
  • Elastase
  • Neutrophil
  • Protease inhibitor
  • Ulinastatin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

A human urinary protease inhibitor (ulinastatin) inhibits neutrophil extracellular release of elastase during cardiopulmonary bypass. / Hiyama, Atsuko; Takeda, Junzo; Kotake, Yoshifumi; Morisaki, Hiroshi; Fukushima, Kazuaki.

In: Journal of Cardiothoracic and Vascular Anesthesia, Vol. 11, No. 5, 08.1997, p. 580-584.

Research output: Contribution to journalArticle

@article{c3d4861bfc9a44a9a16409a9a2fb3b67,
title = "A human urinary protease inhibitor (ulinastatin) inhibits neutrophil extracellular release of elastase during cardiopulmonary bypass",
abstract = "Objectives: To determine the benefits of a human urinary protease inhibitor (ulinastatin) on postoperative pulmonary dysfunction associated with neutrophil activation during cardiopulmonary bypass. Design: A prospective, randomized, clinical study. Setting: The study was performed at Keio University Hospital, Tokyo. Participants: Eighteen adult patients scheduled for primary cardiac surgery. Interventions: The patients were randomly assigned either to the control group (n = 8) or to the group (n = 10) receiving ulinastatin (600,000 U in total). Measurements and Main Results: Human neutrophil ability to release elastase in response to N- formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP) in vitro was measured before and after cardiopulmonary bypass, together with plasma levels of neutrophil elastase complex, interleukin-8, and C3a. Intrapulmonary shunt fraction was then calculated. Neutrophil elastase release in response to fMLP significantly increased in the control group, but remained unchanged in the ulinastatin group. In addition, ulinastatin minimized the increase of plasma neutrophil elastase, independently of the production of interleukin-8 or C3a. Simultaneously, ulinastatin ameliorated the increase of intrapulmonary shunt, which was correlated with extracellular elastase release. Conclusions: Ulinastatin attenuated the elevation of fMLP-induced elastase release, which was associated with the deterioration of gas exchange during cardiopulmonary bypass. The administration of this agent has a potential to lessen the risk of postperfusion lung injury.",
keywords = "Cardiopulmonary bypass, Elastase, Neutrophil, Protease inhibitor, Ulinastatin",
author = "Atsuko Hiyama and Junzo Takeda and Yoshifumi Kotake and Hiroshi Morisaki and Kazuaki Fukushima",
year = "1997",
month = "8",
doi = "10.1016/S1053-0770(97)90008-2",
language = "English",
volume = "11",
pages = "580--584",
journal = "Journal of Cardiothoracic and Vascular Anesthesia",
issn = "1053-0770",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - A human urinary protease inhibitor (ulinastatin) inhibits neutrophil extracellular release of elastase during cardiopulmonary bypass

AU - Hiyama, Atsuko

AU - Takeda, Junzo

AU - Kotake, Yoshifumi

AU - Morisaki, Hiroshi

AU - Fukushima, Kazuaki

PY - 1997/8

Y1 - 1997/8

N2 - Objectives: To determine the benefits of a human urinary protease inhibitor (ulinastatin) on postoperative pulmonary dysfunction associated with neutrophil activation during cardiopulmonary bypass. Design: A prospective, randomized, clinical study. Setting: The study was performed at Keio University Hospital, Tokyo. Participants: Eighteen adult patients scheduled for primary cardiac surgery. Interventions: The patients were randomly assigned either to the control group (n = 8) or to the group (n = 10) receiving ulinastatin (600,000 U in total). Measurements and Main Results: Human neutrophil ability to release elastase in response to N- formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP) in vitro was measured before and after cardiopulmonary bypass, together with plasma levels of neutrophil elastase complex, interleukin-8, and C3a. Intrapulmonary shunt fraction was then calculated. Neutrophil elastase release in response to fMLP significantly increased in the control group, but remained unchanged in the ulinastatin group. In addition, ulinastatin minimized the increase of plasma neutrophil elastase, independently of the production of interleukin-8 or C3a. Simultaneously, ulinastatin ameliorated the increase of intrapulmonary shunt, which was correlated with extracellular elastase release. Conclusions: Ulinastatin attenuated the elevation of fMLP-induced elastase release, which was associated with the deterioration of gas exchange during cardiopulmonary bypass. The administration of this agent has a potential to lessen the risk of postperfusion lung injury.

AB - Objectives: To determine the benefits of a human urinary protease inhibitor (ulinastatin) on postoperative pulmonary dysfunction associated with neutrophil activation during cardiopulmonary bypass. Design: A prospective, randomized, clinical study. Setting: The study was performed at Keio University Hospital, Tokyo. Participants: Eighteen adult patients scheduled for primary cardiac surgery. Interventions: The patients were randomly assigned either to the control group (n = 8) or to the group (n = 10) receiving ulinastatin (600,000 U in total). Measurements and Main Results: Human neutrophil ability to release elastase in response to N- formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP) in vitro was measured before and after cardiopulmonary bypass, together with plasma levels of neutrophil elastase complex, interleukin-8, and C3a. Intrapulmonary shunt fraction was then calculated. Neutrophil elastase release in response to fMLP significantly increased in the control group, but remained unchanged in the ulinastatin group. In addition, ulinastatin minimized the increase of plasma neutrophil elastase, independently of the production of interleukin-8 or C3a. Simultaneously, ulinastatin ameliorated the increase of intrapulmonary shunt, which was correlated with extracellular elastase release. Conclusions: Ulinastatin attenuated the elevation of fMLP-induced elastase release, which was associated with the deterioration of gas exchange during cardiopulmonary bypass. The administration of this agent has a potential to lessen the risk of postperfusion lung injury.

KW - Cardiopulmonary bypass

KW - Elastase

KW - Neutrophil

KW - Protease inhibitor

KW - Ulinastatin

UR - http://www.scopus.com/inward/record.url?scp=0030769416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030769416&partnerID=8YFLogxK

U2 - 10.1016/S1053-0770(97)90008-2

DO - 10.1016/S1053-0770(97)90008-2

M3 - Article

C2 - 9263089

AN - SCOPUS:0030769416

VL - 11

SP - 580

EP - 584

JO - Journal of Cardiothoracic and Vascular Anesthesia

JF - Journal of Cardiothoracic and Vascular Anesthesia

SN - 1053-0770

IS - 5

ER -